Skip to content
Disclosery

13F-HR filed by Finepoint Capital LP

Finepoint Capital LP filed this 13F-HR for the quarter ended 2023-09-30, filed 2023-11-13, with 30 holding rows worth $200,795,271.

Accession
0000904454-23-000604
Filer
CIK 1608126
Filed
2023-11-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2023

A holdings report, 30 entries on the cover page, a total value of $200,795,271 stated on the cover page (in dollars after the unit check, H1), rows summing to $200,795,271 with VALUE read as dollars as filed, 13F file number 028-16580. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock331,416$18,890,712dollars as filed
AMICUS THERAPEUTICS INC03152W109COM1,489,025$18,106,544dollars as filed
SAREPTA THERAPEUTICS INC803607100COM145,357$17,620,176dollars as filed
PROTHENA CORP PLC SHSG72800108Stock349,300$16,853,725dollars as filed
LAKEFRONT BIOTHERAPEUTICS NV36315X101SPON ADR458,659$15,846,668dollars as filed
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR163,772$15,335,610dollars as filed
SPRINGWORKS THERAPEUTICS INC85205L107COM556,928$12,876,175dollars as filed
CYTOKINETICS INC23282W605COM NEW431,693$12,717,676dollars as filed
CEREVEL THERAPEUTICS HLDNG I15678U128COM563,345$12,297,821dollars as filed
REVOLUTION MEDICINES INC COM76155X100Stock427,000$11,819,360dollars as filed
ACADIA PHARMACEUTICALS INC004225108COM556,553$11,598,565dollars as filed
ARVINAS INC04335A105COM504,700$9,912,308dollars as filed
TRAVERE THERAPEUTICS INC89422G107COM895,821$8,008,640dollars as filed
MORPHIC HLDG INC61775R105COM325,356$7,453,906dollars as filed
RELAY THERAPEUTICS INC COM75943R102Stock870,870$7,324,017dollars as filed
SOLID BIOSCIENCES INC83422E204COMMON STOCK961,251$2,422,353dollars as filed
FIRST LT ACQUISITION GROUP I320703101CL A125,000$415,625dollars as filed
ARES ACQUISITION CORPORATIONG33032122*W EXP 02/02/202504,706$333,611dollars as filed
BRIDGETOWN HOLDINGS LTDG1355U121*W EXP 09/30/202895,000$304,300dollars as filed
CHURCHILL CAPITAL CORP VII17144M110*W EXP 02/29/202548,000$168,784dollars as filed
CALIDI BIOTHERAPEUTICS INC320703119*W EXP 03/14/202655,200$144,144dollars as filed
COMPASS DIGITAL ACQUISITION COg2476c123WT459,906$101,271dollars as filed
CHURCHILL CAPITAL CORP VI17143W119*W EXP 02/17/202540,000$86,400dollars as filed
ROSS ACQUISITION II CORPg7641c114WT439,666$49,023dollars as filed
CONCORD ACQUISITION II CORP20607u116WT408,333$42,589dollars as filed
SWIFTMERGE ACQUISITION CORPG63836111*W EXP 12/13/202490,000$34,594dollars as filed
SUMMIT HEALTHCARE ACQUISITIONg9845f117WT489,999$17,150dollars as filed
MARBLEGATE ACQUISITION CORP56608A113*W EXP 08/31/202735,000$13,524dollars as filed
HOME PLATE ACQUISITION CORP43734R111*W EXP 09/30/202690,000$0dollars as filedValue filed as zero, left out of ratios.
CHURCHILL CAPITAL CORP V17144T115*W EXP 10/29/202612,000$0dollars as filedValue filed as zero, left out of ratios.

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000904454-23-000604this filing2023-11-13acceptance time not in the bulk data set